Inflammation  >>  Erbitux (cetuximab) 
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
INTERLINK-1, NCT04590963 / 2019-004770-25: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Hourglass Jul 2022 - Dec 2022 : Data from P3 INTERLINK-1 trial in combination with monalizumab for r/r SCCHN
Active, not recruiting
3
370
Europe, Canada, Japan, US, RoW
Monalizumab, IPH2201, Cetuximab, Erbitux, Placebo
AstraZeneca, Innate Pharma
Squamous Cell Carcinoma of the Head and Neck
05/22
06/24

Download Options